TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception
News
A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food and ... Read more